UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 30,455 Shares of Novavax, Inc. (NASDAQ:NVAX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its holdings in Novavax, Inc. (NASDAQ:NVAX) by 12.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 224,325 shares of the biopharmaceutical company’s stock after selling 30,455 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.14% of Novavax worth $2,833,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in NVAX. Amalgamated Bank increased its position in shares of Novavax by 26.9% during the second quarter. Amalgamated Bank now owns 4,887 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 1,036 shares in the last quarter. Ensign Peak Advisors Inc grew its position in shares of Novavax by 3.0% in the second quarter. Ensign Peak Advisors Inc now owns 44,900 shares of the biopharmaceutical company’s stock valued at $568,000 after purchasing an additional 1,300 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Novavax by 38.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock valued at $77,000 after buying an additional 1,598 shares during the period. Victory Capital Management Inc. lifted its holdings in shares of Novavax by 12.0% in the 3rd quarter. Victory Capital Management Inc. now owns 19,292 shares of the biopharmaceutical company’s stock worth $244,000 after acquiring an additional 2,072 shares during the last quarter. Finally, Banque Cantonale Vaudoise lifted its position in shares of Novavax by 500.0% during the second quarter. Banque Cantonale Vaudoise now owns 3,000 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 2,500 shares in the last quarter. 53.04% of the stock is owned by hedge funds and other institutional investors.

Novavax Price Performance

NVAX opened at $9.11 on Friday. The stock’s 50 day moving average price is $9.53 and its 200 day moving average price is $12.17. The stock has a market cap of $1.46 billion, a P/E ratio of -4.03 and a beta of 2.02. Novavax, Inc. has a 12 month low of $3.53 and a 12 month high of $23.86.

Novavax (NASDAQ:NVAX) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.07. The business had revenue of $84.51 million during the quarter, compared to the consensus estimate of $65.80 million. The firm’s revenue for the quarter was down 54.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.26) earnings per share. Equities analysts anticipate that Novavax, Inc. will post -1.44 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on NVAX shares. Jefferies Financial Group decreased their price objective on shares of Novavax from $31.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday, October 16th. HC Wainwright reaffirmed a “buy” rating and set a $19.00 price target on shares of Novavax in a report on Tuesday. Finally, B. Riley reissued a “buy” rating and issued a $26.00 price objective (up from $23.00) on shares of Novavax in a research note on Thursday, October 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $17.83.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.